Edwards Lifesciences Corp

詳細情報 Edwards Lifesciences Corp 企業名

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

企業情報

企業コードEW

会社名Edwards Lifesciences Corp

上場日Mar 27, 2000

設立日1999

最高経営責任者「CEO」Mr. Bernard J. Zovighian

従業員数15800

証券種類Ordinary Share

決算期末Mar 27

本社所在地One Edwards Way

都市IRVINE

証券取引所NYSE Consolidated

国United States of America

郵便番号92614

電話番号19492502500

ウェブサイトhttps://www.edwards.com

企業コードEW

上場日Mar 27, 2000

設立日1999

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)

25.71K

+15.67%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Larry L. Wood

Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart

186.44K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - JAPAC (Japan, Greater China and Asia Pacific)

25.71K

+15.67%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.21K

+44.48%

収益内訳

通貨: USD更新時刻: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

事業別USD

会社名

収益

比率

Transcatheter Aortic Valve Replacement

4.11B

75.49%

Surgical Heart Valve Therapy

981.30M

18.04%

Transcatheter Mitral and Tricuspid Therapies

352.10M

6.47%

地域別USD

会社名

収益

比率

United States

3.21B

58.94%

Europe

1.32B

24.30%

Rest of the world

572.00M

10.52%

Japan

339.80M

6.25%

事業別

地域別

事業別USD

会社名

収益

比率

Transcatheter Aortic Valve Replacement

4.11B

75.49%

Surgical Heart Valve Therapy

981.30M

18.04%

Transcatheter Mitral and Tricuspid Therapies

352.10M

6.47%

株主

更新時刻: Fri, May 16

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

株主統計

比率

The Vanguard Group, Inc.

11.75%

BlackRock Institutional Trust Company, N.A.

5.50%

Wellington Management Company, LLP

4.97%

State Street Global Advisors (US)

4.40%

JP Morgan Asset Management

2.79%

Other

70.59%

種類

株主統計

比率

Investment Advisor/Hedge Fund

43.18%

Investment Advisor

31.74%

Hedge Fund

5.45%

Research Firm

2.22%

Pension Fund

2.12%

Bank and Trust

1.92%

Sovereign Wealth Fund

1.55%

Individual Investor

0.92%

Endowment Fund

0.82%

Other

10.09%

機関投資家保有株

更新時刻: Sun, Jan 19

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q1

2583

528.48M

90.08%

-16.96M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

2023Q1

2495

522.98M

86.26%

-32.79M

2022Q4

2485

532.76M

86.16%

-12.94M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

68.87M

11.71%

+6.55M

+10.50%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

31.74M

5.4%

-1.09M

-3.33%

Dec 31, 2024

Wellington Management Company, LLP

33.21M

5.65%

+1.68M

+5.32%

Dec 31, 2024

State Street Global Advisors (US)

25.81M

4.39%

-457.01K

-1.74%

Dec 31, 2024

JP Morgan Asset Management

10.76M

1.83%

+6.05M

+128.20%

Dec 31, 2024

Citadel Advisors LLC

9.42M

1.6%

+7.43M

+372.91%

Dec 31, 2024

Geode Capital Management, L.L.C.

13.65M

2.32%

+126.19K

+0.93%

Dec 31, 2024

Fisher Investments

9.78M

1.66%

+696.97K

+7.68%

Dec 31, 2024

Jennison Associates LLC

7.51M

1.28%

+7.01M

+1.40K%

Dec 31, 2024

Walter Scott & Partners Ltd.

9.41M

1.6%

-720.79K

-7.12%

Dec 31, 2024

詳細を見る

76.970USD

Edwards Lifesciences Corp

76.970

概要

企業名